ciprofloxacin has been researched along with Hepatic Failure in 8 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In the survival study, a dose-response effect of ciprofloxacin on survival was observed (ciprofloxacin: 10 mg/kg, 10%; 50 mg/kg, 26%; and 100 mg/kg, 35%) with the results in the 100-mg/kg-treated group being significant when compared with the 5% survival rate in saline-treated controls (P < ." | 5.30 | The beneficial effects of ciprofloxacin on survival and hepatic regenerative activity in a rat model of fulminant hepatic failure. ( Assy, N; Gauthier, T; Kaita, KD; Meyers, AF; Minuk, GY; Zhang, M, 1998) |
| " After intravenous dosing of ciprofloxacin (10-30 mg kg(-1)), ciprofloxacin levels in plasma and brain were measured in normal rats (Wistar, male, 10-week-old) and those with acute renal and hepatic injuries which were induced by uranyl nitrate and carbon tetrachloride (CCl4), respectively." | 5.30 | Distribution of ciprofloxacin into the central nervous system in rats with acute renal or hepatic failure. ( Hirano, H; Ichikawa, N; Iwamoto, K; Naora, K, 1999) |
| " Fluoroquinolones (norfloxacin and ciprofloxacin), third-generation cephalosporins (G3) (ceftriaxone and cefotaxime) and trimethoprim-sulfamethoxazole (SXT) are recommended for preventing infections in patients with cirrhosis or liver failure." | 4.12 | Evaluation of the current guidelines for antibacterial therapy strategies in patients with cirrhosis or liver failure. ( Dong, Y; Du, Q; Han, R; Shi, L; Sun, D; Teng, M; Wang, T; Wang, Y; Zhang, T; Zhang, Y; Zheng, G, 2022) |
| " Ciprofloxacin and dexamethasone were used to treat 11 patients diagnosed on blood culture as having typhoid fever." | 3.70 | Differentiation of typhoid fever from fulminant hepatic failure in patients presenting with jaundice and encephalopathy. ( Chakraborty, A; Jalihal, A; Kamath, PS, 2000) |
| " In the survival study, a dose-response effect of ciprofloxacin on survival was observed (ciprofloxacin: 10 mg/kg, 10%; 50 mg/kg, 26%; and 100 mg/kg, 35%) with the results in the 100-mg/kg-treated group being significant when compared with the 5% survival rate in saline-treated controls (P < ." | 1.30 | The beneficial effects of ciprofloxacin on survival and hepatic regenerative activity in a rat model of fulminant hepatic failure. ( Assy, N; Gauthier, T; Kaita, KD; Meyers, AF; Minuk, GY; Zhang, M, 1998) |
| " After intravenous dosing of ciprofloxacin (10-30 mg kg(-1)), ciprofloxacin levels in plasma and brain were measured in normal rats (Wistar, male, 10-week-old) and those with acute renal and hepatic injuries which were induced by uranyl nitrate and carbon tetrachloride (CCl4), respectively." | 1.30 | Distribution of ciprofloxacin into the central nervous system in rats with acute renal or hepatic failure. ( Hirano, H; Ichikawa, N; Iwamoto, K; Naora, K, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (50.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, Y | 2 |
| Sun, D | 1 |
| Wang, Y | 1 |
| Du, Q | 1 |
| Zhang, Y | 1 |
| Han, R | 1 |
| Teng, M | 1 |
| Zhang, T | 1 |
| Shi, L | 1 |
| Zheng, G | 1 |
| Wang, T | 1 |
| San-Juan, R | 1 |
| Aguado, JM | 1 |
| Lumbreras, C | 1 |
| Fortun, J | 1 |
| Len, O | 1 |
| Munoz, P | 1 |
| Montejo, M | 1 |
| Moreno, A | 1 |
| Cordero, E | 1 |
| Blanes, M | 1 |
| Ramos, A | 1 |
| Torre-Cisneros, J | 1 |
| López-Medrano, F | 1 |
| Carratala, J | 1 |
| Moreno, E | 1 |
| Kojima, H | 1 |
| Kaita, KD | 2 |
| Hawkins, K | 1 |
| Uhanova, J | 1 |
| Minuk, GY | 2 |
| Fuchs, S | 1 |
| Simon, Z | 1 |
| Brezis, M | 1 |
| Pfeiffer, M | 1 |
| Reiter, C | 1 |
| Assy, N | 1 |
| Gauthier, T | 1 |
| Zhang, M | 1 |
| Meyers, AF | 1 |
| Naora, K | 1 |
| Ichikawa, N | 1 |
| Hirano, H | 1 |
| Iwamoto, K | 1 |
| Kamath, PS | 1 |
| Jalihal, A | 1 |
| Chakraborty, A | 1 |
1 trial available for ciprofloxacin and Hepatic Failure
| Article | Year |
|---|---|
Use of fluoroquinolones in patients with chronic hepatitis C virus-induced liver failure.
Topics: Alanine Transaminase; Anti-Infective Agents; Ciprofloxacin; Double-Blind Method; Hepatitis C, Chroni | 2002 |
7 other studies available for ciprofloxacin and Hepatic Failure
| Article | Year |
|---|---|
Evaluation of the current guidelines for antibacterial therapy strategies in patients with cirrhosis or liver failure.
Topics: Anti-Bacterial Agents; Cefotaxime; Ciprofloxacin; Humans; Liver Cirrhosis; Liver Failure | 2022 |
Selective intestinal decontamination with fluoroquinolones for the prevention of early bacterial infections after liver transplantation.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Ciprofloxacin; Female; Fluoroquinolones; H | 2011 |
Fatal hepatic failure associated with ciprofloxacin.
Topics: Aged; Aged, 80 and over; Ciprofloxacin; Humans; Liver Failure; Male | 1994 |
Who is withholding information?
Topics: Adverse Drug Reaction Reporting Systems; Ciprofloxacin; Drug Industry; Germany; Humans; Liver Failur | 1994 |
The beneficial effects of ciprofloxacin on survival and hepatic regenerative activity in a rat model of fulminant hepatic failure.
Topics: Alanine Transaminase; Animals; Anti-Infective Agents; Ciprofloxacin; Disease Models, Animal; DNA; Im | 1998 |
Distribution of ciprofloxacin into the central nervous system in rats with acute renal or hepatic failure.
Topics: Animals; Anti-Infective Agents; Central Nervous System; Ciprofloxacin; Liver Failure; Male; Rats; Ra | 1999 |
Differentiation of typhoid fever from fulminant hepatic failure in patients presenting with jaundice and encephalopathy.
Topics: Adult; Aged; Alkaline Phosphatase; Anti-Infective Agents; Aspartate Aminotransferases; Ciprofloxacin | 2000 |